{"denoms":[{"counts":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"147"},{"groupId":"BG002","value":"302"}],"units":"Participants"}],"groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received intravenous (IV) infusion of 2.5 milligram (mg)/kilogram (kg) belantamab mafodotin on Day 1 of Cycle 1 and 1.9 mg/kg on Day 1 of Cycle 2 onwards in each 28-day cycle, in combination with oral 4 mg per day Pomalidomide capsule on Days 1 to 21 of each 28-day cycle; and oral 40 mg per day Dexamethasone tablet on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, initiation of another anti-myeloma therapy or end of study, whichever occurs first.","id":"BG000","title":"Belantamab Mafodotin+Pomalidomide+Dexamethasone"},{"description":"Participants with RRMM received oral 4 mg per day Pomalidomide capsule on Days 1 to 14 of each 21-day cycle, in combination with subcutaneous (SC) injection of 1.3 mg/meter\\^2(m\\^2) Bortezomib on Days 1, 4, 8, 11, of each 21-day cycle for Cycles 1 through 8, and on Days 1, 8, of each 21-day cycle for Cycles 9+, and oral 20 mg Dexamethasone tablet on Days 1, 2, 4, 5, 8, 9, 11, 12, of each 21-day cycle for Cycles 1 through 8 and then on Days 1, 2, 8, 9, every 3 Weeks (Q3W) from Cycles 9 onwards until disease progression, death, unacceptable toxicity, withdrawal of consent, initiation of another anti-myeloma therapy or end of study, whichever occurs first.","id":"BG001","title":"Pomalidomide+Bortezomib+Dexamethasone"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.56","value":"65.5"},{"groupId":"BG001","spread":"10.03","value":"66.7"},{"groupId":"BG002","spread":"9.31","value":"66.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"YEARS"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"121"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"99"},{"groupId":"BG001","value":"82"},{"groupId":"BG002","value":"181"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"133"},{"groupId":"BG001","value":"127"},{"groupId":"BG002","value":"260"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"42"}]}],"title":"Others"}],"description":"Race categories (Asian, native Hawaiian OR other pacific islander, and mixed race where 0\\<n\\<11) are combined into 'Others' category to maintain participant confidentiality and privacy as the study is evaluating a rare disease.","paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}]}